MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc.,a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System
February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment
August 1, 2023: Francis Medical today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Vanquish minimally invasive water vapor ablation therapy
July 19, 2023: Francis Medical today announced the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer
January 26, 2023: Francis Medical has appointed to its board of directors Andrew Cleeland, a leader with extensive experience in healthcare innovation and the development and deployment of new medical technologies
September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022
June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments
September 29, 2020: Francis Medical Adds Urology Company Coloplast to Its Roster of Investors. The $4 million equity investment will support the company in optimizing its product design and executing a pivotal U.S. study
June 9, 2020: Francis Medical, Inc. announces the enrollment of their first patient in the company’s VAPOR 1 clinical study, an early feasibility study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for the treatment of prostate cancer
October 16, 2019: Dr. Jonathan Jarow joins Francis Medical, Inc. as the company’s chief medical officer (CMO) to lead Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer
December 13, 2018: Francis Medical announces the completion of a $18.0 million round of Series A funding. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures (an affiliate of Solas BioVentures Fund), Tonkawa, and Boston Scientific. Francis Medical plans to use this capital to further develop the company's cancer ablation therapy
The Vanquish® Water Vapor Ablation System is indicated for the thermal ablation of targeted prostate tissue via a transurethral approach. The FDA has not evaluated the Vanquish System for the treatment of any disease, including prostate cancer, or evaluated the Vanquish System for any long-term prostate cancer treatment outcomes.
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.